Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1569 ARTÍCULOS , VIENDO DEL 1036 AL 1050

Anti-Aβ drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease

Lee D , Lee G , Yoon DS .

Analyst. 2018 May 15;143(10):2204-2212. doi: 10.1039/c7an02013a.

The GABAergic system as a therapeutic target for Alzheimer's disease

Calvo-Flores Guzmán B, Vinnakota C, Govindpani K, Waldvogel HJ, Faull RLM, Kwakowsky A.

J Neurochem. 2018 Sep;146(6):649-669. doi: 10.1111/jnc.14345. Epub 2018 Aug 1.

Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework

Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR, Kukull WA, Mohs R, Khachaturian ZS.

Alzheimers Dement. 2018 Apr;14(4):532-534. doi: 10.1016/j.jalz.2018.03.003.

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable

Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, Maruff P, Miller DS, Tong G, Tome MB, Murray ME, Nelson PT, Sano M, Mattsson N, Sultzer DL, Montine TJ, Jack CR Jr, Kolb H, Petersen RC, Vemuri P, Canniere MZ, Schneider JA, Resnick SM, Romano G, van Harten AC, Wolk DA, Bain LJ, Siemers E.

Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002.

Efficacy of Transcranial Direct Current Stimulation Combined with Cognitive Training in the Treatment of Apathy in Patients with Alzheimer's Disease: Study Protocol for a Randomized Trial

Nguyen JP, Boutoleau-Bretonniere C, Lefaucheur JP, Suarez A, Gaillard H, Chapelet G, Abad S, Van Langhenhove A, Nizard J, de Decker L.

Rev Recent Clin Trials. 2018;13(4):319-327. doi: 10.2174/1574887113666180416153316.

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy

Verma S, Kumar A, Tripathi T, Kumar A.

J Pharm Pharmacol. 2018 Aug;70(8):985-993. doi: 10.1111/jphp.12919. Epub 2018 Apr 16.

Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide

Cehlar O, Skrabana R, Revajova V, Novak M.

Bratisl Lek Listy. 2018;119(4):201-204. doi: 10.4149/BLL_2018_037.

Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms

Loi SM, Eratne D, Kelso W, Velakoulis D, Looi JC.

Australas Psychiatry. 2018 Aug;26(4):358-365. doi: 10.1177/1039856218766123. Epub 2018 Apr 19.

Benefit of Oleuropein Aglycone for Alzheimer's Disease by Promoting Autophagy

Cordero JG, García-Escudero R, Avila J, Gargini R, García-Escudero V.

Oxid Med Cell Longev. 2018 Feb 20;2018:5010741. doi: 10.1155/2018/5010741. eCollection 2018.

Accelerating Alzheimer's disease drug innovations from the research pipeline to patients

Goldman DP, Fillit H, Neumann P.

Alzheimers Dement. 2018 Jun;14(6):833-836. doi: 10.1016/j.jalz.2018.02.007. Epub 2018 Apr 18.

Cold Atmospheric Plasmas: A Novel and Promising Way to Treat Neurological Diseases

Xiong Z.

Trends Biotechnol. 2018 Jun;36(6):582-583. doi: 10.1016/j.tibtech.2018.04.003. Epub 2018 Apr 21.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R.

Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25.

Technological Solutions for Older People with Alzheimer's Disease: Review

Maresova P, Tomsone S, Lameski P, Madureira J, Mendes A, Zdravevski E, Chorbev I, Trajkovik V, Ellen M, Rodile K.

Curr Alzheimer Res. 2018;15(10):975-983. doi: 10.2174/1567205015666180427124547.

Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions

Lee JH, Jahrling JB, Denner L, Dineley KT.

J Alzheimers Dis. 2018;64(s1):S427-S453. doi: 10.3233/JAD-179923.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias